Patents by Inventor Charlotte Moira Norfor Allerton
Charlotte Moira Norfor Allerton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7902188Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO, F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.Type: GrantFiled: July 2, 2009Date of Patent: March 8, 2011Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Andrew Douglas Baxter, Andrew Simon Cook, David Hepworth, Stephen Kwok-Fung Wong
-
Patent number: 7576081Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.Type: GrantFiled: June 19, 2006Date of Patent: August 18, 2009Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Andrew Douglas Baxter, Andrew Simon Cook, David Hepworth, Stephen Kwok-Fung Wong
-
Publication number: 20090005354Abstract: The present invention provides for compounds of formula (I): which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.Type: ApplicationFiled: September 10, 2008Publication date: January 1, 2009Applicant: Pfizer, Inc.Inventors: Charlotte Moira Norfor Allerton, Andrew Simon Cook, David Hepworth, Duncan Charles Miller
-
Patent number: 7323462Abstract: Compounds of formula (I), (Ia) and (Ib) useful as a medicament.Type: GrantFiled: December 2, 2003Date of Patent: January 29, 2008Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Andrew Douglas Baxter, Andrew Simon Cook, David Hepworth, Stephen Kwok-Fung Wong
-
Publication number: 20050288270Abstract: The present invention provides for compounds of formula (I): which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.Type: ApplicationFiled: May 26, 2005Publication date: December 29, 2005Inventors: Charlotte Moira Norfor Allerton, Andrew Simon Cook, David Hepworth, Duncan Charles Miller
-
Patent number: 6958402Abstract: Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, are novel.Type: GrantFiled: March 29, 2004Date of Patent: October 25, 2005Assignee: Pfizer, Inc.Inventors: Charlotte Moira Norfor Allerton, David John Bull, Mark Edward Bunnage, Robert John Maguire, John Steele
-
Patent number: 6949577Abstract: The present invention provides compounds of formula (I) as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIa inhibitors suitable for use in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.Type: GrantFiled: March 17, 2003Date of Patent: September 27, 2005Assignee: Pfizer, Inc.Inventors: Charlotte Moira Norfor Allerton, Julian Blagg, Mark Edward Bunnage, John Steele
-
Patent number: 6919457Abstract: Compounds according to formula (I) wherein n is 1-4, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7 and R8 are each independently selected from hydrogen and optionally substituted C1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: GrantFiled: March 31, 2004Date of Patent: July 19, 2005Assignee: Pfizer, Inc.Inventors: Charlotte Moira Norfor Allerton, Mark Edward Bunnage, John Steele
-
Publication number: 20040254164Abstract: Compounds according to formula (I) wherein n is 0-3, R′ is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: ApplicationFiled: March 29, 2004Publication date: December 16, 2004Applicant: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, David John Bull, Mark Edward Bunnage, Robert John Maguire, John Steele
-
Patent number: 6809200Abstract: A process is provide for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (III), (IV) or (V) wherein the variables are as defined in the specification. The reaction is conducted in the presence of −OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent.Type: GrantFiled: July 26, 2001Date of Patent: October 26, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Keith Michael DeVries, Laurence James Harris, Philip Charles Levett, Joanna Teresa Negri, David James Rawson, Albert Shaw Wood
-
Publication number: 20040192668Abstract: Compounds according to formula (I) wherein n is 1-4, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7 and R8 are each independently selected from hydrogen and optionally substituted C1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: ApplicationFiled: March 31, 2004Publication date: September 30, 2004Applicant: Pfizer IncInventors: Charlotte Moira Norfor Allerton, Mark Edward Bunnage, John Steele
-
Patent number: 6794387Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, X, Y and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.Type: GrantFiled: March 14, 2002Date of Patent: September 21, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Kevin Neil Dack, Mark Ian Kemp
-
Patent number: 6784185Abstract: Compounds of general formula I: or pharmaceutically or veterinarily acceptable salts, solvates, polymorphs or pro-drugs thereof wherein: wherein R1, R2, R3, R4, X and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.Type: GrantFiled: March 14, 2002Date of Patent: August 31, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Mark Ian Kemp
-
Patent number: 6759426Abstract: Compounds according to formula (I) wherein n is 1-4, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7 and R8 are each independently selected from hydrogen and optionally substituted C1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: GrantFiled: January 22, 2003Date of Patent: July 6, 2004Assignee: Pfizer IncInventors: Charlotte Moira Norfor Allerton, Mark Edward Bunnage, John Steele
-
Patent number: 6756373Abstract: There is provided a compound of formula I: wherein X represents O or NR5 R4 represents H, halo, cyano, nitro, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13, NR16Y(O)R17, N[Y(O)R17]2, SOR18, SO2R19, C(O)AZ, lower alkyl, lower alkenyl, lower alkynyl, Het, alkylHet, aryl, alkylaryl (which latter seven groups are all optionally substituted with one or more substituents selected from halo, cyano, nitro, lower alkyl, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13 and SO2NR14R15) which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g., cGMP PDE5) is desired.Type: GrantFiled: October 6, 2000Date of Patent: June 29, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Graham Nigel Maw, David James Rawson
-
Patent number: 6713496Abstract: Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-8 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: GrantFiled: January 22, 2003Date of Patent: March 30, 2004Assignee: Pfizer IncInventors: Charlotte Moira Norfor Allerton, David John Bull, Mark Edward Bunnage, Robert John Maguire, John Steele
-
Publication number: 20030236420Abstract: The present invention provides compounds of formula (I) 1Type: ApplicationFiled: March 17, 2003Publication date: December 25, 2003Inventors: Charlotte Moira Norfor Allerton, Julian Blagg, Mark Edward Bunnage, John Steele
-
Publication number: 20030199522Abstract: Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: ApplicationFiled: January 22, 2003Publication date: October 23, 2003Applicant: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, David John Bull, Mark Edward Bunnage, Robert John Maguire, John Steele
-
Publication number: 20030191107Abstract: Compounds according to formula (I) wherein n is 1-4, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7 and R8 are each independently selected from hydrogen and optionally substituted C1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.Type: ApplicationFiled: January 22, 2003Publication date: October 9, 2003Applicant: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Mark Edward Bunnage, John Steele
-
Publication number: 20020198223Abstract: Compounds of general formula I: 1Type: ApplicationFiled: March 14, 2002Publication date: December 26, 2002Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Mark Ian Kemp